| Formulary Chapter 6: Endocrine system - Full Chapter
|
|
| Chapter Links... |
 NICE NG28: Type 2 diabetes in adults: management |
| DVLA guidance |
| NICE Guidance on prescribing |
| Details... |
| 06.06 |
Drugs affecting bone metabolism |
|
|
Calcitriol
|
Second Choice
|
|
|
|
Disodium Pamidronate
|
Formulary
|
|
MHRA: Bisphosphonates: atypical femoral fractures
|
Alendronic Acid
|
Formulary
|
|
MHRA: Bisphosphonates: atypical femoral fractures
NICE TA464: Bisphosphonates for treating osteoporosis
TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
|
CALCITONIN
|
Formulary
|
CALCITONIN (SALMON)/SALCATONIN - Red
CALCITONIN SALMON/ CALCITONIN - Red
|
|
|
Ibandronic acid
(Injection)
|
Formulary
|
|
MHRA: Bisphosphonates: atypical femoral fractures
|
Ibandronic acid
(150mg tabs )
|
Formulary
|
|
MHRA: Bisphosphonates: atypical femoral fractures
|
Ibandronic acid
(50mg tabs)
|
Formulary
|
Dudley
Sandwell
ESCA Sandwell only
Walsall
Wolverhampton
|
ESCA: Ibandronic acid 50mg-Sandwell only
MHRA: Bisphosphonates: atypical femoral fractures
|
PAMIDRONATE DISODIUM
|
Formulary
|
|
|
|
RISEDRONATE SODIUM 30mg
|
Formulary
|
|
|
|
ROMOSOZUMAB
|
Formulary
|
Evenity - Red
|
NICE TA 791: Romosozumab for treating severe osteoporosis
|
Sodium Clodronate (Calsteon®, Loron 520® )
|
Formulary
|
Dudley
Sandwell
ESCA- Sandwell
Walsall
Wolverhampton
|
ESCA: Sodium clodronate-Sandwell only
MHRA: Bisphosphonates: atypical femoral fractures
|
Teriparatide
|
Formulary
|
Red - Forsteo
Red - Movymia
Red - Terrosa
|
NICE TA161: Osteoporosis - secondary prevention (including Teriparatide)
|
Zoledronic acid
|
Formulary
|
Red - Aclasta
Red - Zometa
|
MHRA: Bisphosphonates: atypical femoral fractures
NICE TA464: Bisphosphonates for treating osteoporosis
|
|
|
|
|
|
|
|
|
| 06.06 |
Osteoporosis |
|
|
| 06.06.01 |
Calcitonin and parathyroid hormone |
|
|
Calcitonin (salmon) / Salcatonin
|
Formulary
|
Injection
Nasal spray
For hospital use only
|
NICE TA161: Osteoporosis - secondary prevention (including strontium ranelate)
|
| 06.06.02 |
Bisphosphonates and other drugs affecting bone metabolism |
|
|
|
|
|
|
|
|
| 06.06.02 |
Bisphosphonates |
|
|
Alendronic acid (Binosto®)
(effervescent tablets)
|
Third Choice
|
|
MHRA: Bisphosphonates: atypical femoral fractures
NICE TA464:Bisphosphonates for treating osteoporosis
|
Etidronate disodium
(tablets)
|
Formulary
|
In line with NICE
|
MHRA; Bisphosphonates: atypical femoral fractures
NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
|
|
|
| 06.06.02 |
Denosumab |
|
|
Denosumab (Prolia®)
|
Formulary
|
Dudley
Sandwell
ESCA-Denosumab-Sandwell only
Walsall
Wolverhampton
with RiCaD
Wolverhampton only
|
ESCA: Denosumab (Prolia)-Sandwell only
NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
|
Denosumab (Xgeva®)
|
Formulary
|
For specialist use only in line with NICE TA265
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance (TA265 )
|
| 06.06.02 |
Strontium renelate |
|
|
Strontium ranelate
|
Formulary
|
|
|
|
| .... |
| Non Formulary Items |
Alendronic Acid
(Oral solution)
|
Non Formulary
|
Removed from formulary in Decemeber 2016, replaced by effervescent tablets |
|
|
ALENDRONIC ACID
|
Non Formulary
|
ALENDRONIC ACID / Fosamax Once Week - Black
ALENDRONIC ACID/COLECALCIFEROL - Black
ALENDRONIC ACID/COLECALCIFEROL / Bentexo - Black
ALENDRONIC ACID/COLECALCIFEROL / Fosavance - Black |
|
|
Alendronic Acid (Fosamax®)
|
Non Formulary
|
|
|
|
Alendronic Acid (Fosamax® Once Weekly)
|
Non Formulary
|
|
|
|
Alendronic Acid with colecalciferol (Fosavance®)
|
Non Formulary
|
|
|
|
CALCITRIOL (Rocaltrol®)
|
Non Formulary
|
|
|
|
Disodium Eitdronate (Didronel PMO®)
|
Non Formulary
|
|
|
|
Disodium Etidronate (Didronel®)
|
Non Formulary
|
|
|
|
PARATHYROID HORMONE
|
Non Formulary
|
Preotact - BLACK |
|
|
RISEDRONATE 5MG
|
Non Formulary
|
|
|
|
Risedronate Sodium (Actonel®)
|
Non Formulary
|
Actonel - Black
RISEDRONATE/CALCIUM CARBONATE/COLECALCIFEROL - Black
RISEDRONATE/CALCIUM CARBONATE/COLECALCIFEROL / Actonel Combi - Black
|
UKMI Q&A: Can oral bisphosphonates be given to people with renal impairment to treat osteoporosis?
MHRA: Bisphosphonates: atypical femoral fractures
NICE TA464: Bisphosphonates for treating osteoporosis
TA 161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
|
Tiludronic Acid (Skelid®)
|
Non Formulary
|
|
|
|
| |
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
|
